Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsSafety and efficacy of azacitidine in myelodysplastic syndromesDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsEpigenetic regulators and their impact on therapy in acute myeloid leukemiaPotential use of histone deacetylase inhibitors in cancer therapyCombating the epigenome: epigenetic drugs against non-Hodgkin's lymphomaA perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, nrf2, and epigenomicsTrials with 'epigenetic' drugs: an updateHistone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancyOvercoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanateSynergistic interactions between HDAC and sirtuin inhibitors in human leukemia cellsPanobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cellsPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Clinical Toxicities of Histone Deacetylase Inhibitors.Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia.Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).Differentiation therapy of leukemia: 3 decades of development.Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.Emerging therapies for acute myeloid leukemia.Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivoA phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemiaPhase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.The NF (Nuclear factor)-κB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukaemia cells.Leukaemogenesis: more than mutant genesClinical development of demethylating agents in hematologyTargeting histone deacetyalses in the treatment of B- and T-cell malignancies.Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors.Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicDemethylating agents in myeloid malignancies.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Interpreting clinical assays for histone deacetylase inhibitors.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.Novel agents for the treatment of childhood acute leukemia.Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
P2860
Q21198868-8A6816F2-696A-401B-9F3F-FC9FDD719FBBQ24596561-212D0E47-66E0-4603-AB05-4DF3A019C50EQ26749421-874FFA7F-19AF-45A1-B343-6B58F712AB45Q26765402-4B69C3BB-EEEC-47C7-BA60-FAD4C591CE2EQ26769594-4E22AFD9-80EC-40BC-9F2B-9CE2EA106A1EQ26851166-2FBBCD67-069C-40DB-A603-EEB58735661FQ26852571-09EC2AE1-476A-43D0-8375-467AAB74B4E8Q27000542-049DB860-7876-4054-ADDC-690259279ECCQ28082536-782B5C60-88C9-4B89-85F6-54205EF51708Q28383320-71F5F441-83F7-41DB-B40C-F35A6350B7C1Q28476348-027E7029-D03C-4347-9888-F194A2E2DF8CQ28533896-356CCBC0-CF45-4241-BD91-7B721DF333CCQ28535006-59D070F4-8AA0-4D38-8FAB-73513A9D682DQ31135325-20B57444-A0EA-4F3B-9344-04FF7A6D5024Q33386193-0477DF3A-0DD8-47E8-898B-2411DB06B78CQ33395173-E85EF17A-808D-4303-840C-4D8889DF7275Q33409795-188E361A-D3FC-4C8D-99F2-EFBC85AC0E5FQ33437309-D325285C-1F9D-41C3-BE28-BECBD3334F67Q33576363-9A868907-8EFF-47C9-B5FC-29A5F0ECA523Q33737214-CEAB6018-E55D-4D94-8B7C-D5BD7B8B69BBQ33775647-1039AD64-5849-4DAF-989F-B371810B83E6Q33831971-EC79038D-2E50-436A-AE3F-CA156AD92009Q33896749-510EB1CC-B167-4380-A8BB-AE40B5298D6BQ34014818-D63735DE-A019-475B-9E67-287FA2B4E3D6Q34107482-9E727BBD-78FC-4BF0-84DD-CA3899500F2EQ34176804-0E9946EB-B656-4295-A6D6-ACD47ED02399Q34275371-586A09B8-2A57-4C09-AE3E-C58877F14DC4Q34395179-E016FE21-24D7-4D3D-9641-2EC14013F4F8Q34414452-4B71C140-7468-4DA1-BBCF-B76C355A7129Q34416994-E6837B28-871F-4150-A58F-49D1765C62C3Q34621838-5398EDE6-37F0-4338-8A58-DCBEE70CBAA0Q34808616-AAEDBD54-2CE6-4D3C-9F62-B937C356B057Q34817365-B4F03A20-2432-4329-833F-6AE7C7FBCC87Q34847863-A82228B5-F130-4FD4-8483-2AC1B88BBBC7Q35001132-89106E07-798E-4923-8D30-3A247F3924FDQ35003657-4BE72662-9446-4D55-BEBC-4995FB431404Q35022833-643C6F04-C458-47B5-9EDB-347A25F2893CQ35058556-4C083E9E-C1B1-4C56-A38C-15279C62E913Q35192790-BA1D0ABB-B74A-4F8D-89E2-881900C6C227Q35214924-11ECD00E-FEBE-4E7D-A141-FA5823740AF3
P2860
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@ast
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@en
type
label
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@ast
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@en
prefLabel
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@ast
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@en
P2093
P2860
P50
P1433
P1476
Phase 1 study of the oral isot ...... nhibitor MGCD0103 in leukemia.
@en
P2093
Ann Kalita
Caroline Rousseau
Claire Bonfils
Eric Laille
Gregory Reid
Jeffrey M Besterman
Marja Dubay
Mark Minden
Robert E Martell
P2860
P304
P356
10.1182/BLOOD-2007-10-115873
P407
P577
2008-05-21T00:00:00Z